Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled in 4 early-phase trials were pooled. Rates of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Roberts, Andrew W., Ma, Shuo, Kipps, Thomas J., Coutre, Steven E., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Byrd, John C., Humphrey, Kathryn, Zhou, Lang, Chyla, Brenda, Nielsen, Jacqueline, Potluri, Jalaja, Kim, Su Young, Verdugo, Maria, Stilgenbauer, Stephan, Wierda, William G., Seymour, John F.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2019
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624969/
https://ncbi.nlm.nih.gov/pubmed/31023700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2018882555
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires